Description
Retatrutide supplied as a research reagent for in-vitro laboratory use. Every lot is assayed by reverse-phase HPLC to ≥98% purity, with identity confirmed by mass spectrometry and residual water content checked by Karl Fischer titration. Purity is verified across multiple independent laboratories, and material is sourced across multiple manufacturers so the highest-purity batch can be selected for release.
Specification
- CAS number: 2381089-83-2
- Physical form: Lyophilised powder
- Purity: ≥98% by RP-HPLC
- Storage: 2°C – 8°C, protect from light
Research findings
Unlike most compounds in this index, the retatrutide literature consists of human clinical trial data:
- A triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors; reported in cell-culture studies as less potent than the endogenous ligands at the human GCG and GLP-1 receptors and more potent at the human GIP receptor, with a pharmacokinetic half-life of approximately 6 days [1, 3]
- Phase 1b, people with type 2 diabetes [4]
- Phase 2, adults with obesity without type 2 diabetes [1]
- Phase 2, people with type 2 diabetes [2]
Regulatory status
RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION. Supplied strictly for in-vitro laboratory research by qualified professionals. Not a medicine, supplement, cosmetic or food. Must not be administered to humans or animals.
Vial and carton labels show 99% purity — the specification we aim for on every batch. Our guaranteed minimum is ≥98% by RP-HPLC, and the measured result for each batch appears on its certificate of analysis.
Reviews
There are no reviews yet.